Application value of drug-coated balloon in interventional therapy of situ coronary artery lesions in patients with acute coronary syndrome and its effect on thrombus precursor protein
10.3760/cma.j.issn.1673-4904.2019.11.003
- VernacularTitle: 药物涂层球囊在急性冠状动脉综合征患者原位冠状动脉病变介入治疗中的应用价值及对血栓前体蛋白的影响
- Author:
Shuo LU
1
;
Fengxia HOU
1
;
Xiaoqun ZHENG
2
Author Information
1. Department of Cardiology, Center Hospital of Changchun City, Changchun 130051, China
2. Department of Cardiology, Dalian Central Hospital, Dalian 116033, China
- Publication Type:Journal Article
- Keywords:
Acute coronary syndrome;
Ultrasonography, interventional;
Drug-eluting stents;
Drug-coated balloon;
Thrombus precursor protein
- From:
Chinese Journal of Postgraduates of Medicine
2019;42(11):970-973
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of intravascular ultrasound guidance drug-coated balloon (DCB) in percutaneous coronary intervention (PCI) of situ coronary artery lesions in patients with acute coronary syndrome (ACS), and its effect on thrombus precursor protein (TpP).
Methods:Seventy-eight patients with ACS in Central Hospital of Changchun City from January 2015 to January 2019 were selected, including 46 cases with unstable angina pectoris and 32 cases with acute non-ST-segment elevation myocardial infarction. The patients were divided into DCB group (38 cases) and drug-eluting stent (DES) group (40 cases) by random digits table method. Intravascular ultrasound was used to guide PCI in both groups, and DCB and DES were used respectively. Coronary angiography was performed immediately and 6 months after PCI in both groups. Minimum lumen diameter (MLD) was measured by QCA system, and the lumen loss (LLL) was calculated at 6 months after PCI. Plasma TpP before PCI, 1 and 6 months after PCI was measured by enzyme-linked immunosorbent assay (ELISA). Major adverse cardiovascular events (MACE) including cardiac death, myocardial infarction and target lesion revascularization (TLR) were followed up 1, 3, 6 and 12 months after PCI.
Results:Immediately after PCI, there was no statistical difference in MLD between DCB group and DES group: (1.87 ± 0.23) mm vs. (2.16 ± 0.15) mm, P>0.05; 6 months after PCI, the LLL in DCB group was significantly smaller than that in DES group: (0.31 ± 0.28) mm vs. (0.48 ± 0.19) mm, and there was statistical difference (P<0.05). There were no significant differences in the incidences of myocardial infarction, TLR and cardiac death in DCB group (P>0.05). Before PCI and 6 months after PCI, there was no statistical difference in TpP between 2 groups (P>0.05); 1 month after PCI, the TpP in DCB group was significantly lower than that in DES group: (15.31 ± 6.13) mg/L vs. (19.46 ± 8.24) mg/L, and there was statistical difference (P<0.05).
Conclusions:DCB is an accurate and effective treatment for ACS patients with situ coronary artery disease under the intravascular ultrasound guidance, and it can reduce the risk of thrombosis.
